READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure—a systematic review and network meta-analysis of randomised trials

@article{Tger2019READYRE,
  title={READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure—a systematic review and network meta-analysis of randomised trials},
  author={Tobias T{\"a}ger and Hanna Fr{\"o}hlich and Mirjam Seiz and Hugo A. Katus and Lutz Frankenstein},
  journal={Heart Failure Reviews},
  year={2019},
  volume={24},
  pages={461-472}
}
The majority of patients with chronic heart failure (HF) receive long-term treatment with loop diuretics. [] Key Method We searched PubMed, clinicaltrials.gov, the Cochrane Central Register of Controlled Trials and the European Union Clinical Trials Register for randomised clinical trials exploring the efficacy of the loop diuretics azosemide, bumetanide, furosemide or torasemide in patients with HF. Comparators included placebo, standard medical care or any other active treatment. The primary endpoint was…
Role of loop diuretics in the treatment of acute heart failure
TLDR
The effect of torasemide on mortality reduction in patients with heart failure, seen in some studies, requires further evaluation, and the choice of optimal diuretic treatment strategy in acute heart failure requires knowledge about differences in the characteristics of loop diuretics available in Poland, furosemide and tor asemide.
Impact of Loop Diuretic on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction
TLDR
Loop diuretic use is recommended in order to alleviate symptoms, improve exercise capacity, and reduce hospitalizations in patients with heart failure and their use should be limited to the lowest dose necessary to maintain euvolemia.
Outcomes of diuretics in rheumatic heart disease with compensated chronic heart failure: a retrospective study
TLDR
The purpose of this retrospective propensity score‐matched study was to evaluate the superiority of different application approaches and types of diuretics on long‐term outcomes for rheumatic heart disease patients with compensated chronic heart failure.
Treatment outcomes of bumetanide continuous infusion: A systematic review and meta‐analysis
TLDR
With available evidence, continuous bumetanide infusion may be used in the treatment of acute heart failure or volume overload with close monitoring for new‐onset or worsening AKI.
Temporal trends in heart failure medication prescription in a population-based cohort study
TLDR
The use of MR-antagonists for HF remained low and did not change throughout 13 years of follow-up in the general population, while for most patients, few changes were seen in pharmacological management of HF in the 6 months following diagnosis.
Ten things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)
  • H. Bays
  • Medicine, Biology
    American journal of preventive cardiology
  • 2020
Ten things to know about ten cardiovascular disease risk factors
Ten things to know about ten cardiovascular disease risk factors – 2022

References

SHOWING 1-10 OF 93 REFERENCES
Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure.
TLDR
Azosemide, compared with furosemide, reduced the risk of cardiovascular death or unplanned admission to hospital for congestive HF in patients with chronic heart failure.
Should torsemide be the loop diuretic of choice in systolic heart failure?
TLDR
Compared with furosemide, torsemide significantly reduces HF and CV-related hospital readmissions in systolic HF and is associated with a trend in reducing all-cause mortality.
Effects of Long-Acting Loop Diuretics in Heart Failure With Reduced Ejection Fraction Patients With Cardiac Resynchronization Therapy.
TLDR
HFrEF patients taking LLD after CRT implantation might be comparable to those taking short-acting loop diuretics in the treatment of HF and HF-associated arrhythmias.
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.
TLDR
Chronic diuretic use was associated with increased long-term mortality and hospitalizations in a wide spectrum of ambulatory chronic systolic and diastolic HF patients, challenging the wisdom of routine chronic use of diuretics in HF patients who are asymptomatic or minimally symptomatic without fluid retention.
Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure: a report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD).
TLDR
Among patients hospitalized with worsening HF, loop diuretic use at discharge was associated with long-term adverse outcomes, which suggests that routine chronic use ofloop diuretics may be harmful for patients with HF.
Comparative effects of long-acting and short-acting loop diuretics on cardiac sympathetic nerve activity in patients with chronic heart failure
TLDR
It is indicated that azosemide suppresses CSNA compared with furosemide in patients with CHF, a subanalysis of the previously published study which reported that serial 123I-MIBG studies were the most useful prognostic indicator in patientsWith CHF.
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
TLDR
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Furosemide Prescription During the Dry State Is a Predictor of Long-Term Survival of Stable, Optimally Medicated Patients With Systolic Heart Failure
TLDR
Furosemide administration during the dry state in stable, optimally medicated outpatients with HFrEF is unfavorably associated with long-term survival.
...
...